SNA02-48 not checked
Sinovac Life Sciences Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Tetanus
- Main trialPhase 3
- “The primary objective of this clinical trial is to compare the efficacy and safety of SNA02-48 injection with Human Tetanus Immunoglobulin (HTIG) for tetanus prophylaxis.”In the company’s words, NCT07633119 on ClinicalTrials.gov
Other drugs for Tetanus
- DTpaGSK · Phase 3
- LBVDLG Chem · Phase 2/3
- BK1803Tanabe Pharma Corporation · Phase 3
- DiphtheriaChina National Biotec Group Company Limited · Phase 3
- DTcPCanSino Biologics Inc. · Phase 3
- Tdap vaccineChangchun BCHT Biotechnology Co. · Phase 2
Coming up1
- 31 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 31 Mar 2027 | A Phase Ⅲ Clinical Study of SNA02-48 Injection | |
| Phase 1/2Completed | 8 Dec 2025 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026